Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

References

• U.S. Department of Health and Human Services. National diabetes fact sheet, 2007. Atlanta, GA; 2008. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf [Accessed February 18, 2010]
   Google Scholar
• Dall TM, Zhang Y, Chen YJ, et al. The economic burden of diabetes. Health Aff (Millwood) 2010;29:297-303. Epub January 14, 2010
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care 2009(Suppl 1):S13-61
   Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2008;358:2633-5
   PubMed Web of Science ®Google Scholar
• Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-3
   PubMed Web of Science ®Google Scholar
• Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157-67
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• ACE/AACE Diabetes Road Map Task Force. Road map to achieve glycemic goals: Naive to therapy (Type 2). 2008
   Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Avandia Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; 2008
   Google Scholar
• Karalliedde J, Buckingham RE. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf 2007;30:741-53
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005;4:361-70
   PubMedGoogle Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
   PubMed Web of Science ®Google Scholar
• Arulmozhi DK, Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006;28:96-108
   PubMed Web of Science ®Google Scholar
• Exenatide Prescribing Information. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2008
   Google Scholar
• Novo Nordisk Endocrine and Metabolic Drug Advisory Committee. Liraglutide (injection) for the Treatment of Patients with Type 2 Diabetes: NDA 22-341 Briefing Document. 2009
   Google Scholar
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
   PubMed Web of Science ®Google Scholar
• Novo Nordisk Data on File. 2009
   Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Alfonso-Cristancho R, Conner C, et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol 2009;8:12
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-40
   PubMed Web of Science ®Google Scholar
• Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262–5
   Google Scholar
• Berger ML, Bingefors K, Hedblom EC, et al. Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Lawrenceville, NJ: International Society for Pharmacoeconomics and Outcomes Research
   Google Scholar
• Riedel AA, Heien H, Wogen J, et al. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102-10
   PubMed Web of Science ®Google Scholar
• U.K. Prospective Diabetes Study (UKPDS) Group. U.K. prospective diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
   PubMed Web of Science ®Google Scholar
• Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the mrisk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81
   PubMed Web of Science ®Google Scholar
• U.S. Department of Labor BoLS. Consumer Price Index for the Healthcare Sector, 2010
   Google Scholar
• ISPOR Global Health Care Systems Road Map. Reimbursement Processes Around the World. International Society for Pharmacoeconomics and Outcomes Research 2009. Available from: http://www.ispor.org/HTARoadMaps
   Google Scholar
• Medi-Span® Wolters Kluwer. http://www.medi-span.com
   Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Technology appraisal guidance on the use of long-acting insulin analogues, Report No. 53, 2002. National Institute for Clinical Excellence (NICE) 2009. Available from: URL: http://guidance.nice.org.uk/
   Google Scholar
• Currie CJ, Morrissey M, Peters JR. The impact on health-related quality of life (EQ-5D index) in people with type 1 diabetes who experience severe hypoglycaemia. Diabetologia 2005;48:A292-3
   Web of Science ®Google Scholar
• Tunis SL, Minshall ME. Self monitoring of blood glucose in type 2 diabetes: Cost-effectiveness in the United States. Am J Manag Care 2008;14:131-40
   PubMed Web of Science ®Google Scholar
• Carter A, Parker MM, Moffett HZ, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29:1757-63
   PubMed Web of Science ®Google Scholar
• Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
   PubMed Web of Science ®Google Scholar
• Lee TT, Solomon NA, Heidenreich PA, et al. Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997;126:337-46
   PubMed Web of Science ®Google Scholar
• Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997;127:955-65
   PubMed Web of Science ®Google Scholar
• Mark DB, Simons TA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis. Am Heart J 1999;137:S38-40
   PubMed Web of Science ®Google Scholar
• Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982;1:61-80
   Google Scholar
• Tan-Torres Edejer T, Baltussen R, Adam T et al., eds. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. Geneva: World Health Organization, 2003. WHO. http://www.who.int/choice/publications/
   Google Scholar
• Karter AJ, Moffet HH, Liu J, et al. Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. Am J Manag Care 2005;11:262-70
   PubMed Web of Science ®Google Scholar
• Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-53
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157-69
   PubMed Web of Science ®Google Scholar
• Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006;82:280-4
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Effect of liraglutide on blood glucose control in subjects with type 2 diabetes (LEAD-1). Clinical Trials Gov 2009. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT00318422?term=liraglutide&rank=15
   Google Scholar
• George J, Hannah S, Lang CC. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. Cardiovasc Ther 2009;27:83-8
   PubMed Web of Science ®Google Scholar